Sign In
Buy CLVS
$0.151
+0 (+0%)
At Close: Apr 19, 2023
SVB Leerink Maintains Underperform on Clovis Oncology, Lowers Price Target to $4
10:45am, Wednesday, 20'th May 20208 Biotechs Tapping Secondary Markets for $3 Billion
10:53pm, Tuesday, 19'th May 2020
Company stocks drop on dilution, but monies could benefit shareholders down the line Continue reading...
Why Clovis Oncology's Stock Is Trading Lower Today
07:09pm, Tuesday, 19'th May 2020
Clovis Oncology, Inc. (NASDAQ: CLVS) shares are trading lower on Tuesday.Late Monday, the company announced a common stock offering of $85 million. The company announced the pricing of 11 million shar
Seeing An Opportunity In Clovis Oncology (NASDAQ:CLVS)
05:05pm, Tuesday, 19'th May 2020
Today, we revisit Clovis Oncology, whose stock has been one of the many in the space that have disappointed over the past few years. However, the company just g
Clovis Oncology Announces Pricing of Public Offering of Common Stock
12:05am, Tuesday, 19'th May 2020
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before underwri
Clovis Oncology Announces Pricing of Public Offering of Common Stock
12:00am, Tuesday, 19'th May 2020
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price
Clovis Oncology Announces Proposed Offering of Common Stock
09:02pm, Monday, 18'th May 2020
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of common stock. Clovis Oncology intends to offer,...
Clovis Oncology Announces Proposed Offering of Common Stock
08:02pm, Monday, 18'th May 2020
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of common stock.
Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer
03:45pm, Monday, 18'th May 2020
Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.
Clovis Oncology P:rices 11M Share Public Offering of Common Stock @$8.05/Share
12:00am, Monday, 18'th May 2020Clovis Oncology Secures FDA Approval for Rubraca in Prostate Cancer
03:31pm, Saturday, 16'th May 2020
On Friday, Clovis Oncology (NASDAQ: CLVS) gained Food and Drug Administration approval of Rubraca for patients with metastatic castration-resistant prostate tumors that have BRCA mutations. By itself
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious BRC
